Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD

Clinical Pathways GPS

Waste Not Want Not...Role of Clinical Pathways In Rx Waste Management

12/15/2021

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD, discusses reasons why pharmaceutical waste management is emerging as a new major public and environmental health concern.

Richard G. Stefanacci, DO, MGH,...

12/15/2021

Journal of Clinical Pathways

Clinical Pathways GPS

Medicare Drug Benefit ... The ABCDs

10/20/2021

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD, discusses the drug benefits provided under each of the current Medicare Parts and the future of Medicare design.

Richard G. Stefanacci, DO, MGH,...

10/20/2021

Journal of Clinical Pathways

Special Article

Diabetes Clinical Pathways: Going Beyond Treatment Decisions

12/09/2016

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Scott Guerin , PhD;

Diabetes guidelines increasingly go beyond treatment recommendations to take into account quality measures for diabetes care that exist within new value-based systems, addressing the roles and responsibilities of...

...

12/09/2016

Journal of Clinical Pathways

Clinical Pathways GPS

The Future of Clinical Pathways: The Potential Impact of the Presidential Election

10/12/2016

Scott Guerin , PhD;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Although the topic of health care will continue to be a political one, the continued growth of public health care spending suggests that the government will need to continue its shift toward improving the value of...

...

10/12/2016

Journal of Clinical Pathways

Clinical Pathways GPS

Population Health Delivery Through Health Systems and Pharma

09/06/2016

Scott Guerin , PhD;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

As health systems become more prevalent, they are having increasing levels of control over treatment decisions, in coordination with physicians and managed care organizations. As a result of this increased level of...

As...

09/06/2016

Journal of Clinical Pathways

Perspectives

Impact of Government Cost Controls on Treatment Selection for Clinical Pathways

03/08/2016

Scott Guerin , PhD;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Abstract: The increasing emphasis on value-based care has led to the rise of clinical pathways and their use in various health care settings for a number of different disease states. To improve these pathways and...

...

03/08/2016

Journal of Clinical Pathways

Clinical Pathways GPS

Calling it Quits: Addressing Treatment Discontinuation on a Clinical Pathway

03/08/2016

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Donald Ohloma , MS;

Discontinuation of treatment should be considered whenever treatment benefits are exceeded by their burden. When and how patients should be discontinued from treatment, however, may not necessarily be addressed by a...

...

03/08/2016

Journal of Clinical Pathways

Clinical Pathways GPS

The Role of Patient Adherence in Successful Clinical Pathway Implementation

02/16/2016

Scott Guerin , PhD;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

When considering the development of clinical pathways, the pathway itself is only the beginning; optimum outcomes cannot be realized unless patients follow their prescribed treatments. Simply having prescribers write...

When...

02/16/2016

Journal of Clinical Pathways

Clinical Pathways GPS

The Place for Biosimilars in Clinical Pathways

12/14/2015

Scott Guerin , PhD;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Payers and at-risk providers are developing clinical pathways with great specificity regarding the preferred drugs that be used. Increasingly, these pathways will include biosimilar products. There are three major...

Payers...

12/14/2015

Journal of Clinical Pathways